Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2008-03-11
2008-11-25
Gonzalez, Porfirio Nazario (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
C556S055000, C556S056000, C556S061000, C556S063000, C556S105000, C556S108000, C556S131000, C556S136000, C556S148000, C534S010000, C534S011000, C534S015000, C424S001110, C424S009100
Reexamination Certificate
active
07456215
ABSTRACT:
Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
REFERENCES:
patent: 5196412 (1993-03-01), Bradley et al.
patent: 5258376 (1993-11-01), Bernstein
patent: 5281578 (1994-01-01), Bradley et al.
patent: 5525598 (1996-06-01), Collery et al.
patent: 5574027 (1996-11-01), Bernstein
patent: 5650386 (1997-07-01), Leone-Bay et al.
patent: 5866536 (1999-02-01), Leone-Bay et al.
patent: 5883088 (1999-03-01), Bernstein
patent: 5968922 (1999-10-01), Bernstein
patent: 5998397 (1999-12-01), Bernstein
patent: 6004951 (1999-12-01), Bernstein
patent: 6048851 (2000-04-01), Bernstein
patent: 6087354 (2000-07-01), Bernstein
patent: 7297794 (2007-11-01), Gscheidner et al.
patent: 2004/0048777 (2004-03-01), Weidner et al.
patent: 2005/0147662 (2005-07-01), Freeman, Jr.
patent: WO-91/17751 (1991-11-01), None
patent: WO-93/02087 (1993-02-01), None
patent: WO-2006/072070 (2006-07-01), None
Collery, P. et al., “Preclinical Toxicology and Tissue Gallium Distribution of a Novel Antitumour Gallium Compound: Tris (8-Quinolinolato) Gallium (III)”,Anticancer Research 16, (1996),687-691.
Farrar, G. et al., “Tissue Distribution of Gallium Following Administration of the Gallium-Maltol Complex in the Rat: A Model for an Aluminium-Maltol Complex of Neorotoxicological Interest”,Pharmaceutical Sciences Institute, Aston University, (1988),523-525.
Ho, D. H., et al., “Bioavailability Studies of Tetradentate Schiff-Base Gallium Complexes (Salens)”,Metal Ions in Biiology and Medicinevol. 4, (1996),369-371.
Marathe, D. G., et al., “Physco-chemical Investigation on the Complexes of Gallium (III) with Hydroxy Amino Substituted Carboxylic Acids and Hydroxy Ketones”,Nat. Acad. Sci. Letters.vol. 7, No. 5, (1984),153-156.
Chitambar, Christopher R., et al., “Evaluation of Transferrin and Gallium-Pyridoxal Isonicotinoyl Hydrazone as Potential Therapeutic Agents to Overcome Lymphoid Leukemic Cell Resistance to Gallium Nitrate”,Clinical Cancer Research, vol. 2, (Jun. 1996), 1009-1015.
Richardson, D. R., “Cytotoxic Analogs of the Iron(III) Chelator Pyridoxal Isonicotinoly Hydrazone: Effects of Complexation with Copper(II), Gallium(III), and Iron(III) on Their Antiproliferative Activities”,Antimicrobial Agents and Chemotherapy, (Sep. 1997),2061-2063.
Santos, M. A., et al., “N-Carboxyalkyl Derivatives of 3-Hydroxy-4-Pyridinones: Synthesis, Complexation with Fe(III) and Ga(III) and In Vivo Evaluation”,Journal of Inorganic Biochemistry 92. (2002),43-54.
Stojiljkovic, Igor et al., “Non-Iron Metalloporphyrins: Potent Antibacterial Compounds That Exploit Haem/Hb Uptake Systems of Pathogenic Bacteria”,Molecular Microbiology, (1999 31(2)),4299-442.
Sun, Yizhen et al., “Indium(III) and Gallium(III) Complexes of Bis(aminoethanethiol) Ligands with Different Denticities: Stabilities, Molecular Modeling, and in Vivo Behavior”,J. Med. Chem., (1996, 39),458-470.
Weizman, Haim et al., “1,2-Hopobactin: a hydroxamate analog of enterobactin”,The Royal Society of Chemistry, (2000),2013-2014.
Thiel, M. et al., “Tris(8-quinolinolato) Gallium(III), a Novel Orally Applied Antitumor Gallium Compound”,Relevance of Tumor Models for Anticancer Drug Development, (1999, vol. 54),439-443.
Ambulkar, R. S., et al., “Stepwise Stability Constants of Gallium(III) Complexes with Picolinic Acid and 8-Hydroxyquinoline and its Derivaties”,J. Indian Chem. Soc.vol. L11, (Apr. 1975),315-317.
Ambulkar, R. S., et al., “Complexes of Ga(III) with Thiomalic, Thiolactic, Thioglycollic, Malic Glycollic, Lactic & Aspartic Acides, & Alanine & Glycine”,Indian Journal of Chemistry Vo. 14A, (Jun. 1976),424-427.
Arion, Vladimir B., et al., “Synthesis, Structure, Spectroscopic and in Vitro Antitumour Studies of a Novel Gallium(III) Complex with 2-Acetylpyridine N-Dimethylthiosemicarbazone”,Journal of Inorganic Biochemistry 91, (2002),298-305.
Bernstein, Lawrence R., et al., “Chemistry and Pharmacokinetics of Gallium Maltolate, a Compound with High Oral Gallium Bioavailability”,Metal-Based Drugsvol. 7, No. 1, (2000),33-47.
PCT/US06/40986 International Search Report, 2 pages.
Diehl Servilla LLC
Fugit Donna R.
Genta Incorporated
Gonzalez Porfirio Nazario
Whitney Karen M.
LandOfFree
Pharmaceutical gallium compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical gallium compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical gallium compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049072